- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT07584122
Improving Access to PrEP (HIV Prevention Medication) for People in Underserved Areas of Rio de Janeiro
Bringing PrEP to Underserved Communities in Rio de Janeiro: the PrEPOUT Rio Study
This study aims to improve access to HIV prevention using pre-exposure prophylaxis (PrEP) among underserved populations in Rio de Janeiro, including gay and bisexual men, transgender women, and sex workers. Despite the proven effectiveness of PrEP, many people at higher risk of HIV face barriers to accessing and continuing this prevention method, especially those living in socially and economically vulnerable communities.
The study will evaluate whether offering PrEP directly in community-based settings-such as non-governmental organizations, mobile health units, and through telehealth and digital tools-can increase its uptake and continued use. Participants who test negative for HIV will be offered daily oral PrEP, along with counseling and follow-up support. Those who test positive will be referred for appropriate treatment.
The main hypothesis is that delivering PrEP in community settings, combined with supportive strategies like mobile health interventions, will be feasible, acceptable, and more effective in reaching and engaging vulnerable populations, ultimately helping to reduce new HIV infections.
Přehled studie
Postavení
Podmínky
Detailní popis
The PrEPOUT Rio Study is designed to evaluate the implementation of community-based strategies to expand access to and engagement with oral pre-exposure prophylaxis (PrEP) for HIV prevention among underserved populations in Rio de Janeiro and the metropolitan area, including Nova Iguaçu. The study focuses on populations disproportionately affected by HIV, such as gay, bisexual, and other men who have sex with men (MSM), transgender women, other sexual and gender minorities, and sex workers.
The study will be conducted in three phases. The formative phase will use qualitative methods, including focus group discussions with key stakeholders and members of the target population, to identify barriers and facilitators to PrEP uptake and to inform the adaptation of community-based delivery strategies.
In the implementation phase, PrEP will be offered in non-traditional settings, including community-based organizations and mobile health units, aiming to reduce structural and social barriers to access. Trained healthcare staff will provide on-site HIV testing, counseling, and PrEP initiation. Participants who test HIV-negative will be offered daily oral PrEP, while those diagnosed with HIV will be promptly referred for treatment within the public health system. The study will also incorporate supportive strategies such as telehealth consultations and mobile health (mHealth) interventions to enhance adherence, retention, and engagement in care.
The evaluation phase will include both quantitative and qualitative approaches to assess implementation and clinical outcomes. Quantitative data will be collected through structured questionnaires and clinical assessments to evaluate PrEP uptake, adherence, persistence, and HIV incidence, as well as the acceptability and feasibility of the intervention. Qualitative data from follow-up focus groups will provide insights into participants' experiences and perceptions of community-based PrEP delivery models.
The primary objective is to assess the feasibility and acceptability of delivering PrEP in community-based settings. Secondary objectives include evaluating engagement with telehealth and digital tools, identifying barriers and facilitators to PrEP use, and assessing HIV and sexually transmitted infection (STI) outcomes in the study population. The findings are expected to inform scalable strategies to improve equitable access to HIV prevention services in settings with significant social and structural inequalities.
Typ studie
Zápis (Odhadovaný)
Fáze
- Nelze použít
Kontakty a umístění
Studijní kontakt
- Jméno: Beatriz Grinsztejn
- Telefonní číslo: +55 2138659128
- E-mail: beatriz.grinsztejn@gmail.com
Studijní místa
-
-
Rio de Janeiro
-
Nova Iguaçu, Rio de Janeiro, Brazílie, 26030-380
- Nábor
- Hospital Geral de Nova Iguaçu
-
Kontakt:
- José Henrique Pilotto, PhD
- E-mail: pilotto@uninet.com.br
-
Rio de Janeiro, Rio de Janeiro, Brazílie, 21040360
- Nábor
- Instituto Nacional de Infectologia Evandro Chagas
-
Kontakt:
- Emilia Jalil, PhD
- Telefonní číslo: 55 2138659128
- E-mail: emiliajalil@gmail.com
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
- Dítě
- Dospělý
- Starší dospělý
Přijímá zdravé dobrovolníky
Popis
Inclusion Criteria:
- Individuals aged 15 years or older
- Gay, bisexual, and other men who have sex with men (MSM)
- Transgender women and travestis
- Other sexual and gender minorities (SGM)
- Cisgender women in situations of social or economic vulnerability
- Sex workers
- Individuals seeking HIV testing and/or pre-exposure prophylaxis (PrEP)
- HIV-negative at screening
- Willing and interested in initiating PrEP
- Eligible for PrEP according to Brazilian national guidelines
Exclusion Criteria:
- Positive HIV test result at screening or during study participation
- Individuals not eligible for PrEP according to Brazilian national guidelines
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Výzkum zdravotnických služeb
- Přidělení: N/A
- Intervenční model: Přiřazení jedné skupiny
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Community-Based PrEP Delivery
Participants will receive HIV prevention services through a community-based delivery model, including HIV testing, counseling, and initiation of daily oral pre-exposure prophylaxis (PrEP) according to national guidelines.
Services will be provided in non-traditional settings, such as non-governmental organizations and mobile health units, with additional support through telehealth and mobile health (mHealth) strategies to enhance engagement, adherence, and retention in care.
Participants diagnosed with HIV during screening or follow-up will be referred for treatment within the public health system.
|
Participants will receive daily oral pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate/emtricitabine (TDF/FTC), in accordance with Brazilian national guidelines for HIV prevention.
PrEP will be offered to eligible individuals who test HIV-negative at enrollment and during follow-up, with clinical monitoring and counseling provided as part of routine care.
Participants will receive HIV prevention services through community-based delivery strategies designed to reduce barriers to access.
These include provision of services in non-traditional settings such as non-governmental organizations and mobile health units, with on-site HIV testing, counseling, and same-day PrEP initiation by trained healthcare staff.
Participants will have access to telehealth consultations and mobile health (mHealth) interventions to support engagement in care, adherence to PrEP, and retention in follow-up.
These strategies may include remote clinical support, digital communication tools, and tailored adherence support interventions.
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Feasibility of Community-Based PrEP Delivery
Časové okno: Up to 12 months
|
Feasibility will be assessed by the proportion of planned community-based PrEP service delivery activities successfully implemented.
Indicators will include: (1) number of community-based sites activated, (2) number of individuals screened for HIV, and (3) number of participants initiating PrEP.
Results will be summarized using counts and proportions.
|
Up to 12 months
|
|
Acceptability of Community-Based PrEP Delivery
Časové okno: Up to 12 months
|
Acceptability will be assessed using participant-reported outcomes collected through a structured acceptability questionnaire with Likert-scale items.
Scores will range from 1 to 5, with higher scores indicating greater acceptability of the intervention.
|
Up to 12 months
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
PrEP Uptake
Časové okno: Up to 12 months
|
Proportion of eligible participants who initiate PrEP after HIV testing and counseling in community-based settings.
|
Up to 12 months
|
|
PrEP Persistence (Retention in PrEP Care)
Časové okno: Up to 12 months
|
Proportion of participants who remain engaged in PrEP care over time, including continued use of PrEP and attendance at follow-up visits.
|
Up to 12 months
|
|
HIV Incidence
Časové okno: Up to 12 months
|
Number of new HIV infections diagnosed among study participants during the follow-up period.
|
Up to 12 months
|
Spolupracovníci a vyšetřovatelé
Sponzor
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
- Infekce přenášené krví
- Urogenitální onemocnění
- Onemocnění genitálií
- Onemocnění imunitního systému
- Infekce
- RNA virové infekce
- Virová onemocnění
- Přenosné nemoci
- Pohlavně přenosné choroby, virové
- Pohlavně přenosné nemoci
- Lentivirové infekce
- Retroviridae infekce
- Syndromy imunologické nedostatečnosti
- HIV infekce
- Správa zdravotnických služeb
- Poskytování zdravotní péče
- Organické chemikálie
- Heterocyklické sloučeniny, 1 kruh
- Heterocyklické sloučeniny
- Heterocyklické sloučeniny, 2-prsten
- Heterocyklické sloučeniny, fúzované kroužek
- Nukleové kyseliny, nukleotidy a nukleosidy
- Veřejné zdraví
- Životní prostředí a veřejné zdraví
- Puriny
- Deoxycytidin
- Cytidin
- Pyrimidinové nukleosidy
- Pyrimidiny
- Zdravotní služby
- Zdravotnická zařízení pracovní síla a služby
- Preventivní zdravotní služby
- Organofosforové sloučeniny
- Nukleosidy
- Deoxyribonukleosidy
- Organofosfonáty
- Adenine
- Praxe veřejného zdraví
- Řízení péče o pacienty
- Primární prevence
- Tenofovir
- Emtricitabin
- Telemedicína
- Profylaxe před expozicí
Další identifikační čísla studie
- 84111624.4.1001.5262
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na HIV infekce
-
Ottawa Hospital Research InstitutePfizerDokončenoHIV infekce | HIV-1 infekce | Mycobacterium Avium Complex (MAC)Kanada
-
National Institute of Allergy and Infectious Diseases...DokončenoHIV infekce | Infekce Mycobacterium Avium-intracellulareSpojené státy
-
National Institute of Allergy and Infectious Diseases...AbbottDokončenoHIV infekce | Infekce Mycobacterium Avium-intracellulareSpojené státy
-
National Institute of Allergy and Infectious Diseases...DokončenoHIV infekce | Infekce Mycobacterium Avium-IntracellulareSpojené státy
-
National Institute of Allergy and Infectious Diseases...DokončenoHIV infekce | Infekce Mycobacterium Avium-intracellulareSpojené státy
-
National Institute of Allergy and Infectious Diseases...DokončenoHIV infekce | Infekce Mycobacterium Avium-intracellulareSpojené státy
-
National Institute of Allergy and Infectious Diseases...DokončenoHIV infekce | Infekce Mycobacterium Avium-intracellulareSpojené státy, Tanzanie
-
AbbottDokončenoHIV infekce | Intracelulární infekce Mycobacterium AviumSpojené státy, Portoriko
-
AbbottNational Cancer Institute (NCI)DokončenoHIV infekce | Infekce Mycobacterium Avium-intracellulareSpojené státy
-
Aaron Diamond AIDS Research CenterDokončenoHIV infekce | Infekce Mycobacterium Avium-Intracellulare | Tuberkulóza, infekce MycobacteriumSpojené státy